Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSTA4637S in S. aureus Bacteremia
NCT03162250Phase 1Completed
- Sponsor
- Genentech
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of DSTA4637S in Staphylococcus aureus bacteremia (SAB) (4 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events (AEs). Started Jul 2017; status: completed.
02
Drugs
DSTA4637S
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT03162250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162250.